Network News

This post is Part 2 of a two-part blog series. Read part 1: What is a TR‑FRET assay and how is it used in drug discovery? In a previous blog post, we covered the fundamental principles of Time-Resolved Fluorescence (TR) Förster Resonance Energy Transfer (TR-FRET), including how long-lived lanthanide donors like europium enable high-sensitivity, “mix-and-read” assays. Because TR-FRET provides a ratiometric, proximity-based […]

Three researchers at the German Cancer Research Center (DKFZ) have each been awarded a Starting Grant from the European Research Council (ERC) this year. Daniel Kirschenbaum, Lena Kutscher, and Michael Scherer impressed the ERC with their innovative research approaches to fundamental questions in cancer medicine. With the funding, they plan to investigate why certain brain […]

Stephanie Möllmert, independent research group leader at the Max Planck Institute for Medical Research, has been awarded a Starting Grant by the European Research Council (ERC). In the funded project REPROMECH, she plans to investigate the physical and mechanical conditions in the fallopian tube and their significance for the transport of eggs and early embryos. […]

Heidelberg, Germany, 1 September 2026 – BioMed X, a leading innovation engine for pharma, today announced the relocation of its global headquarters to LAB22 at Heidelberg Innovation Park (hip), together with the launch of a global partnership with BioLabs, a leading provider of shared laboratory infrastructure for life science innovators. Over the coming months, BioMed X will relocate its global headquarters […]

Ladenburg, Germany, 28 August 2026 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that its wholly-owned subsidiary, Heidelberg Pharma Research GmbH, has signed a new collaboration agreement with its strategic partner Huadong Medicine Co., Ltd., Hangzhou, China. Huadong Medicine is the second-largest shareholder of Heidelberg Pharma […]

Ladenburg, Germany, 26 August 2026 – Heidelberg Pharma AG (FSE: HPHA), a clinical-stage biotech company developing innovative Antibody Drug Conjugates (ADCs), today announced that the China National Medical Products Administration (NMPA) has granted Clinical Trial Approval for a Phase Ib/II clinical trial evaluating pamlectabart tismanitin (HDP-101), the Company’s novel BCMA-targeting ADC, in combination therapy for the […]

Heidelberg-based biotech company REVIER Therapeutics has officially launched. The company, which emerged from research conducted at the German Centre for Cardiovascular Research (DZHK) and Heidelberg University, is developing a novel therapeutic approach for cardiometabolic diseases. REVIER has raised €6 million in seed funding to advance its development programs. At the heart of REVIER’s approach are […]

The European research project THEODORA is launching during “Gold September”, the international childhood cancer awareness month. Researchers at the Heidelberg Medical Faculty of Heidelberg University, drawing on their expertise in clinical research and precision oncology at Hopp Children’s Cancer Center Heidelberg (KiTZ), are collaborating with Institut Curie in Paris, Prinses Máxima Centrum in Utrecht, and […]

Ruperto Carola in 59th place worldwide – among the “Top 3” in Germany Heidelberg University has achieved top placements in the 2026 Academic Ranking of World Universities. As in the previous year, it is one of the “Top 3” universities in Germany. In the global comparison, Ruperto Carola is in 59th position in this so-called […]